Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the antitumor activity of pazopanib in patients with
metastatic and/or locally advanced unresectable Gastrointestinal Stromal Tumors (GIST)
resistant to imatinib and sunitinib. This is a phase II, randomized, multicentre study.